# LinqMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/linqmed

- Industry: Healthcare Specialists
- Headquarters: Tokyo, Japan
- Website: www.linqmed.co.jp
- Total disclosed funding: $34M
- Latest round: Series B (May 12, 2025)
- Investors on record: 16

## About

Founded in 2022 and based in Chiba, Japan, LinqMed Inc. operates as a developer of cancer treatment that uses radioactive copper which can be traced through a PET scan. In April 2025, LinqMed Inc. raised JPY 2.05 billion in series B funding from new investors Keio Innovation Initiative, Sumitomo Mitsui Trust Bank, LOTTE HOLDINGS CO.,LTD., Mitsubishi UFJ Capital, Nomura SPARX Investment, with participation from returning investors Bio-Sight Capital and Chibagin Capital. The company offers treatment and drugs for cancer patients using copper isotopes. The firm has developed radiopharmaceuticals using copper radioisotope that can be used in the diagnosis of cancer as well as in treatment. The company plans to use the April 2025 funding for research and development expenses, factory operating costs, and recruitment.

## Funding rounds

- Series B, May 12, 2025, $2.1M — Nissay Capital
- Series B, Apr 9, 2025, $17M — Sumitomo Mitsui Trust Bank, Mitsubishi UFJ Capital, Bio-Sight Capital, Chibagin Capital, Keio Innovation Initiative, Nomura SPARX Investment
- Series B, Jan 10, 2025, $9.5M — DBJ Capital, Axil Capital, JIC Venture Growth Investments
- Series A, Dec 22, 2023, $4.8M — Mizuho Capital, Bio-Sight Capital, DBJ Capital, PeptiDream Inc., Taisho Pharmaceutical Co., Ltd., Shiratori Pharmaceutical Co., Ltd., GREEN CORE, IWABUCHI PHARMACEUTICAL CO.,LTD

## Investors

- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A
- Bio-Sight Capital (https://capitalatlas.ai/funds/bio-sight-capital) — Series A, Series B
- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Series A, Series B
- PeptiDream Inc. — Series A
- Taisho Pharmaceutical Co., Ltd. — Series A
- Shiratori Pharmaceutical Co., Ltd. — Series A
- GREEN CORE — Series A
- IWABUCHI PHARMACEUTICAL CO.,LTD — Series A
- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series B
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series B
- Sumitomo Mitsui Trust Bank — Series B
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B
- Chibagin Capital (https://capitalatlas.ai/funds/chibagin-capital) — Series B
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series B
- Nomura SPARX Investment (https://capitalatlas.ai/funds/nomura-sparx-investment) — Series B
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series B